Persistent Systems Partners with NVIDIA to Accelerate AI-Powered Drug Discovery
Persistent Systems partners with NVIDIA to accelerate AI-powered drug discovery for the Healthcare and Life Sciences industry. The collaboration will leverage NVIDIA's AI platform and Persistent's GenMoIVS solution to enhance computational drug discovery and streamline research workflows. The announcement was made on March 17, 2026.
This partnership is significant as it involves a collaboration with a major technology player like NVIDIA, focusing on a high-growth area like AI in drug discovery. The impact is medium as it is a strategic alliance and product launch, the financial impact of which will be seen over time.
The announcement details a strategic partnership with NVIDIA to enhance AI capabilities in drug discovery, which is a positive development for the company's growth in the Healthcare and Life Sciences sector.
Persistent Systems Limited announced a collaboration with NVIDIA to accelerate the development and deployment of AI-powered solutions for the Healthcare and Life Sciences (HLS) industry. This partnership aims to help HLS organizations advance computational drug discovery and enhance research outcomes using Generative AI and advanced analytics.
The collaboration will enable Life Sciences enterprises to move from AI experimentation to production deployments in critical environments by combining Persistent's domain expertise with NVIDIA's full-stack AI platform. Persistent will utilize NVIDIA AI Enterprise for specialized R&D use cases, including preclinical research, by enabling high-fidelity molecular simulation and virtual screening at scale.
Persistent has developed a Generative Molecules and Virtual Screening (GenMoIVS) solution, powered by the NVIDIA BioNeMo platform and NVIDIA NeMo Agent Toolkit. This solution will deliver AI-driven molecular simulations and create intelligent agents to streamline drug discovery workflows. It supports continuous decision-making across virtual screening, candidate prioritization, and experimental planning, enabling a simulation-led approach to de-risk early-stage discovery and accelerate experimental cycles.
Persistent plans to leverage NVIDIA Nemotron open models for further enhancement of its GenMolVS solution and will use NVIDIA accelerated computing, servers, NVIDIA AI Enterprise, and NVIDIA NIM microservices for deploying production-grade AI applications. This infrastructure will expedite cost-effective development and scaling of applications with accurate AI outputs embedded into enterprise workflows.
Ganesh Nathella, Executive Vice President and General Manager - HLS Business at Persistent, stated that the collaboration enables BioPharma clients to use generative molecules and virtual screening in production, transitioning from months-long experiments to AI-driven discovery in days. John Fanelli, Vice President - Enterprise Software at NVIDIA, added that Persistent is empowering biopharma companies with production-grade agentic systems for molecular simulation and virtual screening.
The press release was issued on March 17, 2026.
What to do with a filing like this
Persistent Systems Limited filed this with the NSE as a statutory disclosure, categorised under strategic partnerships. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Persistent Systems Limited. Read the original for the full detail.